Literature DB >> 15914370

Infliximab-associated lymphoproliferative disorders.

Yoshihiko Hoshida, Shigeo Yamamoto, Naoki Wada, Jing-Xian Xu, Toru Sasaki, Katsuyuki Aozasa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914370     DOI: 10.1532/IJH97.05026

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

Review 2.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

4.  Rheumatoid arthritis and cancer risk.

Authors:  L Mellemkjaer; M S Linet; G Gridley; M Frisch; H Møller; J H Olsen
Journal:  Eur J Cancer       Date:  1996-09       Impact factor: 9.162

Review 5.  Rheumatoid arthritis and malignant lymphomas.

Authors:  Eva Baecklund; Johan Askling; Richard Rosenquist; Anders Ekbom; Lars Klareskog
Journal:  Curr Opin Rheumatol       Date:  2004-05       Impact factor: 5.006

6.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2004-06

7.  Incidence of cancer among patients with rheumatoid arthritis.

Authors:  G Gridley; J K McLaughlin; A Ekbom; L Klareskog; H O Adami; D G Hacker; R Hoover; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.